October 29, 2019

Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS)
Fiscal 2019 Third Quarter

(January 1, 2019 - September 30, 2019)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on October 29, 2019 for the first nine months of Fiscal 2019, from January 1, 2019 to September 30, 2019.
- This document is an English translation of the Japanese-language original. The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
  "FY 2019 forecasts" have not been revised from the consolidated earnings forecasts released on February 5, 2019.
- Following the conclusion of an agreement to transfer shares of Kyowa Hakko Bio Co., Ltd., the Bio-Chemicals business is categorized as a discontinued operation, effective the first quarter of Fiscal 2019 for accounting on a consolidated basis. Accordingly, FY 2018 results presented herein have been restated in order to present them similarly to the FY 2019 results.
  Note that the amounts after restatement for the "FY 2018 results Jan - Dec" have not been audited by an audit corporation.
- Figures presented in these materials have been rounded to the nearest tenth.
- Figures inside parenthesis presented in these materials indicate negative values.

Index Page

The average exchange rates for each period were as follows:

Unit: Yen

	FY 2018 results				FY 2019 results			FY 2019 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
USD	110	109	109	110	110	110	109	110
EUR	134	132	131	131	126	125	123	130
GBP	152	151	149	148	143	143	140	145

Contact
Kyowa Kirin Co., Ltd.
Corporate Communications Department
Tel +81 3 5205 7206

Ⅰ. Consolidated Financial Results

1. Trends in consolidated profit

<Accumulative>

Unit: Billions of yen

	FY 2018 results				FY 2019 results				FY 2019 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec
Revenue	66.5	134.3	197.7	271.5	75.8	151.4	225.5	27.7	305.0
Cost of sales	(19.8)	(37.0)	(53.9)	(73.4)	(19.8)	(38.6)	(57.1)	(3.2)	(81.0)
Gross profit	46.7	97.4	143.8	198.1	56.1	112.8	168.4	24.6	224.0
Gross profit to revenue ratio	70.2%	72.5%	72.7%	73.0%	74.0%	74.5%	74.7%	-	73.4%
Selling, general and administrative expenses	(23.5)	(48.3)	(72.3)	(102.1)	(26.7)	(55.3)	(83.9)	(11.6)	(117.5)
Research and development expenses	(10.2)	(21.6)	(32.3)	(45.7)	(11.9)	(24.9)	(37.9)	(5.6)	(52.5)
R&D expenses to revenue ratio	15.3%	16.1%	16.3%	16.8%	15.7%	16.4%	16.8%	-	17.2%
Share of profit (loss) of investments accounted for using equity method	1.4	0.9	0.3	(0.1)	(0.2)	(0.5)	(0.9)	(1.2)	(1.0)
Core operating profit	14.4	28.4	39.5	50.3	17.3	32.2	45.8	6.2	53.0
Core operation profit to revenue ratio	21.6%	21.1%	20.0%	18.5%	22.9%	21.2%	20.3%	-	17.4%
Other income	14.4	14.5	18.3	18.6	0.1	0.2	0.3	(18.0)	
Other expenses	(0.1)	(0.3)	(0.4)	(1.4)	(5.3)	(10.5)	(12.3)	(11.9)	
Finance income (costs)	(0.1)	(0.4)	(0.5)	(0.6)	0.1	(0.0)	(0.3)	0.2	
Profit before tax	28.6	42.2	56.9	66.8	12.3	21.8	33.5	(23.4)	47.0
Income tax expense	(7.7)	(10.7)	(14.1)	(17.6)	(3.0)	(3.2)	(6.5)	7.5	
Ratio of income tax burden	27.0%	25.4%	24.7%	26.3%	24.1%	14.5%	19.6%	-	
Profit from continuing operations	20.9	31.5	42.8	49.2	9.3	18.7	26.9	(15.9)	37.0
Profit from continuing operations to revenue ratio	31.4%	23.5%	21.6%	18.1%	12.3%	12.3%	11.9%	-	12.1%
Profit from discontinued operations	1.1	2.7	4.6	5.2	(1.2)	29.4	29.4	24.8	31.0
Profit	22.0	34.3	47.4	54.4	8.1	48.1	56.3	8.9	68.0
Profit to revenue ratio	33.1%	25.5%	24.0%	20.0%	10.7%	31.7%	25.0%	-	22.3%
EPS (¥/share)	40.20	62.61	86.62	99.40	14.97	89.02	104.48	17.86	126.30
Annual dividend (¥/share)				35.00					40.00
Dividend payout ratio (%)				35.2					31.7
ROE (%)				8.6					10.5

* Profit from discontinued operations is presented separately from continuing operations on the condensed quarterly consolidated statement of profit or loss.
Accordingly, the amounts displayed from revenue through profit from continuing operations are amounts of the continuing operations and exclude the discontinued operations.

<Quarterly>

Unit: Billions of yen

	FY 2018 results				FY 2019 results			
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Revenue	66.5	67.9	63.4	73.8	75.8	75.6	74.0	10.7
Cost of sales	(19.8)	(17.2)	(17.0)	(19.4)	(19.8)	(18.9)	(18.5)	(1.5)
Gross profit	46.7	50.7	46.4	54.4	56.1	56.7	55.6	9.2
Selling, general and administrative expenses	(23.5)	(24.8)	(24.0)	(29.8)	(26.7)	(28.6)	(28.6)	(4.6)
Research and development expenses	(10.2)	(11.4)	(10.6)	(13.4)	(11.9)	(13.0)	(13.0)	(2.3)
Share of profit (loss) of investments accounted for using equity method	1.4	(0.5)	(0.6)	(0.4)	(0.2)	(0.3)	(0.4)	0.2
Core operating profit	14.4	14.0	11.2	10.8	17.3	14.8	13.6	2.4
Other income	14.4	0.1	3.7	0.3	0.1	0.1	0.1	(3.6)
Other expenses	(0.1)	(0.2)	(0.1)	(1.0)	(5.3)	(5.2)	(1.9)	(1.7)
Finance income (costs)	(0.1)	(0.3)	(0.1)	(0.1)	0.1	(0.2)	(0.2)	(0.1)
Profit before tax	28.6	13.6	14.6	10.0	12.3	9.6	11.6	(3.0)
Income tax expense	(7.7)	(3.0)	(3.4)	(3.5)	(3.0)	(0.2)	(3.4)	(0.0)
Profit from continuing operations	20.9	10.6	11.3	6.4	9.3	9.3	8.3	(3.0)
Profit from discontinued operations	1.1	1.6	1.9	0.6	(1.2)	30.6	-	(1.9)
Profit	22.0	12.3	13.1	7.0	8.1	39.9	8.3	(4.9)

<Breakdown of profit for FY 2019 Jan - Sep from discontinued operations>

Unit: Billions of yen

	FY 2018 results				FY 2019 results		
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep
Revenue	18.2	37.8	56.2	75.0	18.1	18.1	18.1
Gross profit	7.1	14.6	22.2	29.0	6.8	6.8	6.8
Core operating profit	1.9	3.8	6.4	8.4	1.3	1.3	1.3
Profit before tax	1.7	3.5	5.9	6.6	(0.6)	43.2	43.2
Profit	1.1	2.7	4.6	5.2	(1.2)	29.4	29.4

* Regarding transactions between continuing operations and discontinued operations, considering the continuity of the transactions in the future, revenue and the expenses generated from transactions between such operations have been eliminated from the results of discontinued operations.

2. Revenue by geographic region (continuing operations)

Unit: Billions of yen

	FY 2018 results					FY 2019 results				FY 2019 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of consolidated revenue	Jan - Mar	Jan - Jun	Jan - Sep	Percentage of consolidated revenue	Jan - Dec	Percentage of consolidated revenue
Japan	45.7	91.4	135.1	183.5	67.6%	48.8	95.5	140.6	62.4%	185.5	60.8%
International	20.8	43.0	62.7	88.0	32.4%	27.1	55.9	84.9	37.6%	119.5	39.2%
Americas	4.2	10.9	14.6	23.0	8.5%	8.9	20.4	32.8	14.5%	50.0	16.4%
Europe	11.5	21.5	31.8	42.3	15.6%	11.8	22.0	31.7	14.1%	45.0	14.8%
Asia	4.9	10.5	16.2	22.5	8.3%	6.3	13.4	20.3	9.0%	24.0	7.9%
Others	0.2	0.1	0.1	0.2	0.1%	0.0	0.1	0.1	0.0%	0.5	0.2%
Total consolidated revenue	66.5	134.3	197.7	271.5	100%	75.8	151.4	225.5	100%	305.0	100%

* Revenue is classified by region or country based on location of customer.

3. Capital expenditures and intangible assets investment (continuing operations)

Unit: Billions of yen

	FY 2018 results				FY 2019 results			FY 2019 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
Capital expenditures (property, plant and equipment)	0.8	1.8	3.3	4.5	2.6	4.5	5.7	10.6
Intangible assets investment	0.6	4.4	5.7	9.0	3.4	3.7	13.2	11.5
Total	1.4	6.2	9.0	13.5	6.0	8.2	18.9	22.1

* Acquisitions of right-of-use assets are not included.

4. Depreciation and amortization (continuing operations)

Unit: Billions of yen

	FY 2018 results				FY 2019 results			FY 2019 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
Depreciation (property, plant and equipment)	1.6	3.5	5.4	7.3	2.5	5.5	8.1	9.3
Amortization (intangible assets)	2.1	4.2	6.2	8.9	2.2	4.5	6.4	8.6
Total	3.8	7.7	11.7	16.2	4.7	10.0	14.5	17.9

Ⅱ. Consolidated Statement of Cash Flows

Unit: Billions of yen

	FY 2018 results				FY 2019 results			
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount
Cash flows from operating activities	19.5	29.8	46.4	56.2	9.2	19.8	38.6	(7.8)
Of which, cash flows of discontinued operations	1.6	2.1	3.5	6.8	6.3	6.3	6.3	2.8
Cash flows from investing activities	(14.5)	(23.0)	(30.8)	(39.9)	29.3	10.6	4.1	35.0
Of which, cash flows of discontinued operations	(2.3)	(4.3)	(5.2)	(6.4)	(1.9)	103.2	103.2	108.4
Cash flows from financing activities	(8.3)	(8.4)	(16.5)	(16.5)	(34.5)	(35.2)	(46.6)	(30.1)
Of which, cash flows of discontinued operations	(0.3)	(0.3)	(0.2)	(0.2)	(0.0)	(0.0)	(0.0)	0.1
Effect of exchange rate changes on cash and cash equivalents	(0.1)	(0.6)	(0.4)	0.4	(0.4)	(0.2)	0.1	0.4
Net increase (decrease) in cash and cash equivalents	(3.5)	(2.2)	(1.3)	0.1	3.7	(4.9)	(3.8)	(2.5)
Transfer to assets held for sale	1.1	1.1	1.1	1.1	(3.6)	-	-	(1.1)
Cash and cash equivalents at beginning of period	14.7	14.7	14.7	14.7	15.9	15.9	15.9	1.2
Cash and cash equivalents at end of period*	12.3	13.6	14.5	15.9	15.9	10.9	12.1	(2.4)
* Cash reserves at end of period								
Cash and cash equivalents at end of period	12.3	13.6	14.5	15.9	15.9	10.9	12.1	(2.4)
+ Loans receivable from parent in excess of three months	168.0	172.4	179.6	181.3	144.6	283.7	283.4	103.8
+ Time deposits whose maturity periods exceed three months	0.0	0.0	0.0	0.0	-	0.8	0.8	0.7
Cash reserves at end of period	180.3	186.0	194.1	197.2	160.5	295.4	296.2	102.1

Ⅲ. Revenue from Main Products

<Accumulative>

Unit: Billions of yen

	Indication / Product name	FY 2018 results				FY 2019 results				FY 2019 forecasts	
		Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change amount	Jan - Dec	%
Japan	*Renal anemia treatment drug* ***Nesp***	12.0	25.6	39.2	53.7	11.8	25.6	32.0	(7.2)		
	Darbepoetin Alfa Injection Syringe [KKF]	-	-	-	-	-	-	5.6	5.6		
	Total	12.0	25.6	39.2	53.7	11.8	25.6	37.6	(1.6)	48.4	90%
	Secondary hyperparathyroidism ***Regpara***	3.6	7.8	10.7	13.3	1.8	3.8	5.2	(5.4)	5.1	38%
	Secondary hyperparathyroidism ***Orkedia***	-	0.4	1.1	2.4	1.2	3.0	4.8	3.7	9.5	397%
	Secondary hyperparathyroidism ***Rocaltrol***	0.9	1.9	2.8	3.8	0.8	1.7	2.7	(0.1)	3.6	96%
	Type-2 diabetes ***Onglyza***	1.6	3.6	5.4	7.4	1.7	3.7	5.5	0.1	7.6	102%
	Cardiovascular (Hypertension & angina pectoris) ***Coniel***	1.2	2.5	3.6	4.8	1.0	2.0	3.0	(0.7)	3.9	81%
	Agent for decreasing the incidence of febrile neutropenia ***G-Lasta***	4.3	9.5	14.8	20.7	5.3	11.5	18.3	3.5	22.8	110%
	Transdermal persistent pain ***Fentos***	1.2	2.6	4.0	5.4	1.1	2.3	3.4	(0.5)	4.8	89%
	Anticancer ***Poteligeo***	0.4	0.9	1.3	1.8	0.4	1.0	1.5	0.2	1.7	96%
	Anticancer ***Rituximab BS [KHK]***	0.3	1.1	2.4	4.3	1.8	4.2	6.8	4.3	8.4	195%
	Chronic idiopathic thrombocytopenic purpura ***Romiplate***	0.7	1.5	2.4	3.2	0.8	1.6	3.0	0.6	4.4	136%
	Antiallergenic ***Allelock***	4.6	7.5	9.7	12.6	4.0	6.4	8.5	(1.3)	9.3	74%
	Antiallergic eyedrops ***Patanol***	7.7	9.7	11.5	13.4	8.5	9.9	11.7	0.2	11.3	84%
	Ulcerative colitis ***Asacol***	0.7	1.5	2.2	2.9	0.6	1.2	1.8	(0.4)	2.2	77%
	Psoriasis vulgaris ***Dovobet***	1.2	2.8	4.2	5.9	1.5	3.4	5.0	0.8	7.8	132%
	Psoriasis ***Lumicef***	0.4	0.9	1.4	2.0	0.5	1.2	1.8	0.5	2.7	134%
	Parkinson's disease ***Nouriast***	1.9	4.4	6.8	9.4	2.2	4.8	7.3	0.5	10.0	107%
	Antiepileptic ***Depakene***	1.3	2.7	4.0	5.3	1.1	2.3	3.3	(0.6)	4.3	82%
	Technology out-licensing	1.1	1.5	2.2	2.7	0.9	1.7	3.7	1.5	4.4	162%
International	*X-linked hypophosphatemia (XLH)* ***Crysvita***	-	0.8	3.2	7.7	5.7	13.4	21.6	18.4		
	Anticancer ***Poteligeo***	-	-	-	2.1	2.4	5.4	8.0	8.0	10.0	478%
	Cancer pain ***Abstral***	3.4	6.5	9.5	12.8	3.1	5.8	8.3	(1.2)	12.3	96%
	Cancer pain ***Pecfent***	1.0	2.0	3.2	4.4	1.1	1.9	2.9	(0.3)	5.0	113%
	Chemotherapy-induced nausea and vomiting drug ***Sancuso***	0.6	1.3	2.1	3.0	0.7	1.4	2.3	0.2	2.9	99%
	Opioid-induced constipation (OIC) ***Moventig***	0.3	0.6	1.0	1.4	0.5	1.0	1.4	0.5	2.5	174%
	Replacement therapy with testosterone for male hypogonadism ***Tostran/Fortesta***	0.6	1.4	2.1	2.8	0.6	1.2	1.6	(0.5)	1.9	68%
	Osteoporosis drug ***Adcal-D3***	0.9	1.8	2.7	3.5	0.8	1.6	2.3	(0.3)	3.1	90%
	Anticancer ***Mitomycin-C***	0.6	1.3	1.7	2.3	0.6	1.0	1.5	(0.2)	2.1	88%
	Renal anemia treatment drug ***Nesp***	1.5	3.1	4.7	6.4	1.7	3.3	4.7	0.0	5.9	93%
	Secondary hyperparathyroidism ***Regpara***	0.7	1.5	2.3	3.2	1.1	2.4	3.8	1.5	3.7	114%
	Agent for decreasing the incidence of febrile neutropenia ***Neulasta/Peglasta***	0.4	1.0	1.7	2.4	1.0	1.9	2.7	1.0	4.2	173%
	Neutropenia treatment drug ***Gran***	1.4	2.7	4.2	5.4	1.5	3.1	4.8	0.6	5.6	104%
	Technology out-licensing	6.5	12.4	13.9	15.8	3.2	5.2	7.9	(6.0)	12.9	82%
	Of which, Benralizumab royalty	0.0	0.5	1.7	3.3	2.0	3.8	6.1	4.4		

* Revenue is classified as Japan or International (other than Japan) based on customer location.
* Revenue from main products does not include revenue from the Early Access Program (EAP).
* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.
* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

Ⅲ. Revenue from Main Products

<Quarterly>

Unit: Billions of yen

	Indication / Product name	FY 2018 results				FY 2019 results			
		Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change amount
Japan	*Renal anemia treatment drug* **Nesp**	12.0	13.6	13.6	14.5	11.8	13.8	6.4	(7.3)
	Darbepoetin Alfa Injection Syringe [KKF]	-	-	-	-	-	-	5.6	5.6
	Total	12.0	13.6	13.6	14.5	11.8	13.8	12.0	(1.7)
	Secondary hyperparathyroidism **Regpara**	3.6	4.2	2.9	2.6	1.8	1.9	1.5	(1.5)
	Secondary hyperparathyroidism ***Orkedia***	-	0.4	0.8	1.3	1.2	1.8	1.8	1.0
	Secondary hyperparathyroidism ***Rocaltrol***	0.9	1.0	0.9	1.0	0.8	0.9	0.9	(0.0)
	Type-2 diabetes ***Onglyza***	1.6	1.9	1.8	2.1	1.7	2.0	1.8	(0.0)
	Cardiovascular (Hypertension & angina pectoris) ***Coniel***	1.2	1.3	1.1	1.2	1.0	1.1	0.9	(0.2)
	Agent for decreasing the incidence of febrile neutropenia ***G-Lasta***	4.3	5.1	5.3	5.9	5.3	6.2	6.8	1.5
	Transdermal persistent pain ***Fentos***	1.2	1.4	1.4	1.4	1.1	1.2	1.1	(0.2)
	Anticancer ***Poteligeo***	0.4	0.5	0.4	0.5	0.4	0.5	0.5	0.1
	Anticancer ***Rituximab BS [KHK]***	0.3	0.8	1.3	1.8	1.8	2.3	2.6	1.3
	Chronic idiopathic thrombocytopenic purpura ***Romiplate***	0.7	0.8	0.8	0.9	0.8	0.9	1.3	0.5
	Antiallergenic ***Allelock***	4.6	2.9	2.3	2.8	4.0	2.4	2.0	(0.2)
	Antiallergic eyedrops ***Patanol***	7.7	2.0	1.7	1.9	8.5	1.4	1.7	0.0
	Ulcerative colitis ***Asacol***	0.7	0.8	0.7	0.7	0.6	0.6	0.6	(0.1)
	Psoriasis vulgaris ***Dovobet***	1.2	1.6	1.4	1.7	1.5	1.9	1.6	0.2
	Psoriasis ***Lumicef***	0.4	0.5	0.5	0.6	0.5	0.7	0.7	0.1
	Parkinson's disease ***Nouriast***	1.9	2.5	2.4	2.6	2.2	2.6	2.5	0.1
	Antiepileptic ***Depakene***	1.3	1.4	1.3	1.3	1.1	1.2	1.1	(0.2)
	Technology out-licensing	1.1	0.4	0.8	0.5	0.9	0.7	2.1	1.3
International	*X-linked hypophosphatemia (XLH)* ***Crysvita***	-	0.8	2.4	4.5	5.7	7.7	8.2	5.9
	Anticancer ***Poteligeo***	-	-	-	2.1	2.4	3.0	2.6	2.6
	Cancer pain ***Abstral***	3.4	3.1	3.1	3.2	3.1	2.7	2.5	(0.6)
	Cancer pain ***Pecfent***	1.0	1.0	1.2	1.2	1.1	0.9	1.0	(0.2)
	Chemotherapy-induced nausea and vomiting drug ***Sancuso***	0.6	0.7	0.8	0.9	0.7	0.7	0.8	0.1
	Opioid-induced constipation (OIC) ***Moventig***	0.3	0.3	0.4	0.4	0.5	0.5	0.5	0.1
	Replacement therapy with testosterone for male hypogonadism ***Tostran/Fortesta***	0.6	0.8	0.7	0.7	0.6	0.6	0.4	(0.3)
	Osteoporosis drug ***Adcal-D3***	0.9	0.9	0.9	0.8	0.8	0.8	0.7	(0.1)
	Anticancer ***Mitomycin-C***	0.6	0.6	0.5	0.6	0.6	0.4	0.5	(0.0)
	Renal anemia treatment drug ***Nesp***	1.5	1.6	1.6	1.7	1.7	1.6	1.4	(0.2)
	Secondary hyperparathyroidism ***Regpara***	0.7	0.8	0.9	0.9	1.1	1.3	1.4	0.5
	Agent for decreasing the incidence of febrile neutropenia ***Neulasta/Peglasta***	0.4	0.6	0.7	0.7	1.0	1.0	0.8	0.1
	Neutropenia treatment drug ***Gran***	1.4	1.3	1.5	1.2	1.5	1.7	1.7	0.2
	Technology out-licensing	6.5	5.9	1.5	1.9	3.2	2.0	2.7	1.2
	Of which, Benralizumab royalty	0.0	0.5	1.2	1.6	2.0	1.8	2.3	1.1

* Revenue is classified as Japan or International (other than Japan) based on customer location.
* Revenue from main products does not include revenue from the Early Access Program (EAP).
* Revenue listed as "Technology out-licensing" specifies revenue from the upfront payment, milestone revenue, and running royalties revenue that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.
* Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

Ⅳ. R&D Pipeline

Filed • Approved antibody protein small molecule As of Sep. 30, 2019

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		**KRN321 Darbepoetin Alfa Injection**	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Filed in CN	Kirin-Amgen	
				Renal Anemia	Approved in ID		
		KHK7580 Evocalcet Oral	Calcimimetic	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Immunology /Allergy		**KHK4827 Brodalumab Injection**	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR	Kirin-Amgen	
					Filed in MY		
					Filed in CN		
					Filed in MO		
Central Nervous System		**KW-6002 Istradefylline Oral**	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Approved in US	In-House	
Other		**◎KRN23 Burosumab Injection**	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in TW	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					Filed in CH		
					Filed in KW		
					Filed in SA		
					Filed in CN		
					Filed in HK		
					Filed in SG		
				FGF23-Related Hypophosphatemic Rickets and Osteomalacia	Approved in JP		
					Filed in KR		

Ph Ⅱ~Ⅲ

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		**◎RTA 402 Bardoxolone Methyl Oral**	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	Phase Ⅲ in JP	Licensed from Reata	
		KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	Phase Ⅲ in CN, KR, TW and HK	Licensed from Mitsubishi Tanabe Pharma	
		◎KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	Phase Ⅱ in JP	Licensed from Ardelyx	
Oncology		**◎KHK2375 Entinostat Oral**	HDAC Inhibitor	Breast Cancer	Phase Ⅱ in JP	Licensed from Syndax	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase Ⅱ in US, EU and others	In-House	POTELLIGENT®
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood	Phase Ⅱ in JP	Kirin-Amgen	
Immunology/ Allergy		**◎KHK4083 Injection**	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase Ⅱ in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology
				Atopic Dermatitis	Phase Ⅱ in JP, US, CA and EU		
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	Phase Ⅲ in JP, KR and TW	Kirin-Amgen	
				Systemic Sclerosis	Phase Ⅲ in JP		
				Palmoplantar Pustulosis	Phase Ⅲ in JP		
		◎ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in *de novo* kidney transplant recipients	Phase Ⅱ in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System		**KW-0761 Mogamulizumab Injection**	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase Ⅲ in JP	In-House	POTELLIGENT®
		◎KW-6356 Oral	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Phase Ⅱ in JP	In-House	
Other		**◎KRN23 Burosumab Injection**	Anti-FGF23 Fully Human Antibody	Tumor Induced Osteomalacia(TIO)/Epidermal Nevus Syndrome (ENS)	Phase Ⅱ in US	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					Phase Ⅱ in JP and KR		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Phase Ⅱ/Ⅲ in KR	Kirin-Amgen	
				Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	Phase Ⅱ/Ⅲ in JP, KR and TW		
				Idiopathic (Immune) Thrombocytopenic Purpura	Phase Ⅲ in CN		

Updated since Jun. 30, 2019 （Area, Stage, Filed, Approved, etc.）

◎ New Molecular Entity

Ⅳ. R&D Pipeline

antibody protein small molecule

Ph Ⅰ

As of Sep. 30, 2019

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		**◎KHK2455 Oral**	IDO1 Inhibitor	Solid Tumor	Phase Ⅰ in US	In-House	Combination with KW-0761
				Urothelial carcinoma	Phase Ⅰ in US	In-House	Combination with avelumab
		◎ME-401 Oral	PI3Kδ Inhibitor	B-cell malignancies	Phase Ⅰ in JP	Licensed from MEI Pharma	
Immunology/ Allergy		**◎KHK4083 Injection**	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase Ⅰ in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
		KHK4323 Injection		Atopic Dermatitis	Phase Ⅰ in JP	In-House	
Central Nervous System		**◎KHK6640 Injection**	Anti–Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase Ⅰ in EU	Licensed from Immunas Pharma	
					Phase Ⅰ in JP		
Others		**KW-3357 Antithrombin Gamma Injection**	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase Ⅰ in EU	In-House	

Updated since Jun. 30, 2019 （Area, Stage, Filed, Approved, etc.）

◎ New Molecular Entity

Updated since Jun. 30, 2019 （Area, Stage, Filed, Approved, etc.）

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		**KRN321 Darbepoetin Alfa Injection**	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia	Approved in ID	Kirin-Amgen	
Immunology /Allergy		**KHK4827 Brodalumab Injection**	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in MO	Kirin-Amgen	
Central Nervous System		**KW-6002 Istradefylline Oral**	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Approved in US	In-House	
Others		**◎KRN23 Burosumab Injection**	Anti-FGF23 Fully Human Antibody	FGF23-Related Hypophosphatemic Rickets and Osteomalacia	Approved in JP	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				X-linked Hypophosphatemia (XLH)	Filed in SG		

Ph Ⅱ~Ⅲ

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology /Allergy		**KHK4827 Brodalumab Injection**	Anti-IL-17 Receptor A Fully Human Antibody	Palmoplantar Pustulosis	Phase Ⅲ in JP	Kirin-Amgen	

Ph Ⅰ

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		**◎KHK2455 Oral**	IDO1 Inhibitor	Urothelial carcinoma	Phase Ⅰ in US	In-House	Combination with avelumab

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		**KW-0761 Mogamulizumab Injection**	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase Ⅰ/Ⅱ in US	In-House	POTELLIGENT® Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)